Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Fulton Bank N.A.

Fulton Bank N.A. increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,293 shares of the medical equipment provider’s stock after buying an additional 67 shares during the period. Fulton Bank N.A.’s holdings in Intuitive Surgical were worth $784,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ISRG. Green Alpha Advisors LLC lifted its holdings in Intuitive Surgical by 6.7% during the second quarter. Green Alpha Advisors LLC now owns 1,838 shares of the medical equipment provider’s stock valued at $628,000 after purchasing an additional 115 shares in the last quarter. Moseley Investment Management Inc. lifted its stake in shares of Intuitive Surgical by 2.5% in the second quarter. Moseley Investment Management Inc. now owns 2,413 shares of the medical equipment provider’s stock worth $825,000 after buying an additional 60 shares in the last quarter. AMF Tjanstepension AB lifted its stake in shares of Intuitive Surgical by 48.3% in the second quarter. AMF Tjanstepension AB now owns 17,310 shares of the medical equipment provider’s stock worth $5,919,000 after buying an additional 5,640 shares in the last quarter. Advance Capital Management Inc. purchased a new position in shares of Intuitive Surgical in the second quarter worth about $225,000. Finally, Level Four Advisory Services LLC lifted its stake in shares of Intuitive Surgical by 3.0% in the first quarter. Level Four Advisory Services LLC now owns 1,357 shares of the medical equipment provider’s stock worth $347,000 after buying an additional 39 shares in the last quarter. 82.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research reports. Sanford C. Bernstein raised their price target on shares of Intuitive Surgical from $350.00 to $365.00 in a research note on Wednesday, May 31st. Mizuho raised their price target on shares of Intuitive Surgical from $300.00 to $370.00 in a research note on Monday, July 17th. Wells Fargo & Company raised their price target on shares of Intuitive Surgical from $310.00 to $386.00 and gave the stock an “overweight” rating in a research note on Friday, July 21st. Raymond James raised their price objective on shares of Intuitive Surgical from $323.00 to $368.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. Finally, Robert W. Baird initiated coverage on shares of Intuitive Surgical in a research report on Tuesday, July 18th. They set an “outperform” rating and a $377.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $343.10.

Insider Transactions at Intuitive Surgical

In other news, Director Amy L. Ladd sold 500 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $305.68, for a total transaction of $152,840.00. Following the completion of the sale, the director now owns 702 shares in the company, valued at approximately $214,587.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Monday, August 7th. The shares were sold at an average price of $310.00, for a total value of $620,000.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $7,848,890. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy L. Ladd sold 500 shares of Intuitive Surgical stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $305.68, for a total transaction of $152,840.00. Following the completion of the transaction, the director now directly owns 702 shares in the company, valued at $214,587.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,309 shares of company stock worth $19,649,321. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Stock Down 2.7 %

Shares of Intuitive Surgical stock opened at $295.54 on Friday. Intuitive Surgical, Inc. has a 52-week low of $180.07 and a 52-week high of $358.07. The company has a 50 day moving average of $315.28 and a 200 day moving average of $296.65. The company has a market capitalization of $103.85 billion, a P/E ratio of 74.07, a P/E/G ratio of 4.25 and a beta of 1.30.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.09. Intuitive Surgical had a net margin of 21.38% and a return on equity of 12.41%. The company had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter in the previous year, the firm earned $0.85 earnings per share. The firm’s quarterly revenue was up 15.4% on a year-over-year basis. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 4.53 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.